Nordea Investment Management AB Has $2.43 Million Position in Emergent Biosolutions, Inc. (EBS)

Nordea Investment Management AB lessened its holdings in Emergent Biosolutions, Inc. (NYSE:EBS) by 3.3% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 60,006 shares of the biopharmaceutical company’s stock after selling 2,076 shares during the quarter. Nordea Investment Management AB owned 0.14% of Emergent Biosolutions worth $2,427,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also modified their holdings of EBS. Northern Trust Corp raised its position in Emergent Biosolutions by 47.2% in the 2nd quarter. Northern Trust Corp now owns 906,731 shares of the biopharmaceutical company’s stock worth $30,747,000 after purchasing an additional 290,863 shares during the period. Dimensional Fund Advisors LP raised its position in Emergent Biosolutions by 7.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,205,712 shares of the biopharmaceutical company’s stock worth $74,795,000 after purchasing an additional 152,029 shares during the period. Rice Hall James & Associates LLC grew its holdings in Emergent Biosolutions by 26.1% in the 2nd quarter. Rice Hall James & Associates LLC now owns 669,617 shares of the biopharmaceutical company’s stock worth $22,707,000 after acquiring an additional 138,611 shares during the last quarter. Peregrine Capital Management LLC grew its holdings in Emergent Biosolutions by 40.8% in the 3rd quarter. Peregrine Capital Management LLC now owns 454,857 shares of the biopharmaceutical company’s stock worth $18,399,000 after acquiring an additional 131,692 shares during the last quarter. Finally, Aberdeen Asset Management PLC UK grew its holdings in Emergent Biosolutions by 7.3% in the 2nd quarter. Aberdeen Asset Management PLC UK now owns 1,737,470 shares of the biopharmaceutical company’s stock worth $58,918,000 after acquiring an additional 118,894 shares during the last quarter. Institutional investors own 92.70% of the company’s stock.

A number of brokerages have issued reports on EBS. Zacks Investment Research raised shares of Emergent Biosolutions from a “hold” rating to a “strong-buy” rating and set a $48.00 price target on the stock in a report on Tuesday, November 28th. Wells Fargo & Company reissued an “outperform” rating and issued a $43.00 price target (up previously from $41.00) on shares of Emergent Biosolutions in a report on Saturday, September 30th. Finally, BidaskClub raised shares of Emergent Biosolutions from a “hold” rating to a “buy” rating in a report on Friday, August 25th. One investment analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $46.00.

Shares of Emergent Biosolutions, Inc. (EBS) opened at $43.86 on Tuesday. The stock has a market cap of $1,815.19, a price-to-earnings ratio of 23.20, a price-to-earnings-growth ratio of 1.21 and a beta of 1.24. Emergent Biosolutions, Inc. has a twelve month low of $26.16 and a twelve month high of $44.97. The company has a debt-to-equity ratio of 0.38, a current ratio of 7.37 and a quick ratio of 6.46.

Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported $0.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.32. The business had revenue of $149.43 million for the quarter, compared to analyst estimates of $124.55 million. Emergent Biosolutions had a net margin of 15.60% and a return on equity of 15.20%. The company’s revenue was up 4.6% on a year-over-year basis. During the same quarter last year, the firm earned $0.56 EPS. equities analysts expect that Emergent Biosolutions, Inc. will post 1.64 earnings per share for the current year.

In other news, Chairman Fuad El-Hibri sold 47,983 shares of Emergent Biosolutions stock in a transaction dated Wednesday, November 29th. The shares were sold at an average price of $41.88, for a total transaction of $2,009,528.04. Following the sale, the chairman now owns 1,550,216 shares of the company’s stock, valued at approximately $64,923,046.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Adam Havey sold 7,885 shares of Emergent Biosolutions stock in a transaction dated Friday, September 8th. The shares were sold at an average price of $37.06, for a total transaction of $292,218.10. Following the sale, the executive vice president now directly owns 33,931 shares in the company, valued at approximately $1,257,482.86. The disclosure for this sale can be found here. In the last three months, insiders sold 279,632 shares of company stock worth $11,288,315. Insiders own 16.50% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Nordea Investment Management AB Has $2.43 Million Position in Emergent Biosolutions, Inc. (EBS)” was originally published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.chaffeybreeze.com/2017/12/05/nordea-investment-management-ab-has-2-43-million-position-in-emergent-biosolutions-inc-ebs.html.

Emergent Biosolutions Profile

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Institutional Ownership by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply